Advertisement
Advertisement
OABI
OmniAb, Inc. Common Stock
4.66
USDSponsored
-0.05
-1.06%
Aug 25, 15:59 UTC -4
Closed
After-Market
4.73
+0.07
+1.46%
OABI Earnings Reports
Positive Surprise Ratio
OABI beat 7 of 15 last estimates.
47%
Next Report
Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
$4.40M
/-$0.11
Implied change from Q2 26 (Revenue/ EPS)
-67.18%
/+120.00%
Implied change from Q3 25 (Revenue/ EPS)
+96.65%
/-21.43%
OmniAb, Inc. Common Stock earnings per share and revenue
On Aug 06, 2026, OABI reported earnings of -0.05 USD per share (EPS) for Q2 26, beating the estimate of -0.12 USD, resulting in a 59.15% surprise. Revenue reached 13.41 million, compared to an expected 4.79 million, with a 180.25% difference. The market reacted with a +37.50% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 5 analysts forecast an EPS of -0.11 USD, with revenue projected to reach 4.40 million USD, implying an increase of 120.00% EPS, and decrease of -67.18% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Altimmune, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.12
Surprise
+14.22%
Aquestive Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.18
Surprise
-70.78%
ARS Pharmaceuticals, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.50
Actual
-$0.63
Surprise
-25.40%
Journey Medical Corporation Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.01
Surprise
+56.33%
MediWound Ltd.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.77
Actual
-$0.77
Surprise
+0.89%
PolyPid Ltd. Ordinary Shares
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.35
Surprise
+9.28%
Talphera, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.06
Actual
-$0.06
Surprise
+11.76%
Nektar Therapeutics
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$2.02
Actual
-$1.23
Surprise
+39.24%
Karyopharm Therapeutics Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.30
Actual
-$2.31
Surprise
-78.16%
Vyome Holdings, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.19
Actual
-$0.10
Surprise
+48.40%
FAQ
What were OmniAb, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, OmniAb, Inc. Common Stock reported EPS of -$0.05, beating estimates by 59.15%, and revenue of $13.41M, 180.25% above expectations.
How did the market react to OmniAb, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 37.5%, changed from $2.24 before the earnings release to $3.08 the day after.
When is OmniAb, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 02, 2026.
What are the forecasts for OmniAb, Inc. Common Stock's next earnings report?
Based on 5
analysts, OmniAb, Inc. Common Stock is expected to report EPS of -$0.11 and revenue of $4.40M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement